RxDoctor Payments Data

Heather Gillespie

Family · Malta, OHNPI 1144779604

Payments from drug & device makers

$769in general payments, 2019–2025

Across 46 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$187
  • AstraZeneca$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
  • Lilly USA, LLC$52
  • Phathom Pharmaceuticals, Inc.$49
  • Novo Nordisk$47
  • plus $239 from 9 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$769 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$2,866
Medicare patients
119
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol190$144,318
OzempicSemaglutide81$101,181
EliquisApixaban115$96,055
TrulicityDulaglutide47$70,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$57,228
XareltoRivaroxaban59$52,718
JardianceEmpagliflozin55$47,344
Breo ElliptaFluticasone/Vilanterol66$37,862
JanuviaSitagliptin Phosphate38$27,766
RybelsusSemaglutide29$27,745
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$21,798
NuedextaDextromethorphan Hbr/Quinidine17$20,239
MounjaroTirzepatide13$16,977
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$16,412
Spiriva RespimatTiotropium Bromide26$15,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$102$153,096203 claims
Novo NordiskOzempic, Rybelsus$47$128,926110 claims
PfizerEliquis$28$96,055115 claims
Lilly USA, LLCTrulicity, Mounjaro$52$87,53760 claims
Boehringer IngelheimJardiance, Spiriva Respimat$15$63,24381 claims
MerckJanuvia, Dulera$35$38,81670 claims
AbbVieSynthroid$187$4,745126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Malta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →